Alzamend Neuro, Inc. announces a convertible note offering and concurrent private placement for up to $25 million
Amount Raised
$25 Million
Round Type
Series A
AtlantaBiotechnologyHealth CareScience And EngineeringDescription
Alzamend Neuro, Inc. has entered into a Securities Purchase Agreement with an institutional investor for the purchase and sale of Series A Convertible Preferred Stock in a registered direct offering, and a concurrent private placement, raising an aggregate of up to $25 million. The proceeds from the financing will be used to initiate additional clinical trials for its product candidates and general working capital purposes.
Quick answer
Alzamend Neuro raised $25 Million in a Series A round, dated May 9, 2024. Alzamend Neuro is based in Atlanta, Georgia, United States.
- How much did Alzamend Neuro raise?
- Alzamend Neuro raised $25 Million in a Series A round on May 9, 2024.
- What does Alzamend Neuro do?
- Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress..
- Where is Alzamend Neuro based and how big is it?
- Alzamend Neuro is based in Atlanta, Georgia, United States. Fundz records about 7 employees.
- Who are the decision-makers at Alzamend Neuro?
- Fundz holds 1 contact at Alzamend Neuro, including the Deputy General Counsel and Vice President of Legal Affairs. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Alzamend Neuro that raised within 45 days of this round, from Fundz verified event records.
- Memo Therapeutics AG raised $22M (Series C) on May 7, 2024.
- Variantyx raised $36M (Funding Round) on April 26, 2024.
- Sydnexis raised $1000K (Series B) on April 24, 2024.
- DeepCure raised $25M (Series A) on April 11, 2024.
- 22nd Century raised $4.2M (Seed) on April 8, 2024.
- Nucleai raised $14M (Funding Round) on April 3, 2024.
Who to call at Alzamend Neuro, and when
A new round usually means Alzamend Neuro is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alzamend Neuro raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alzamend Neuro, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alzamend Neuro. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alzamend Neuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAlzamend Neuro raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.